Press release
Investigation announced for Long-Term Investors in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) over potential Wrongdoing

An investigation on behalf of current long term investors in Akero Therapeutics, Inc. (NASDAQ: AKRO) shares.
Investors who are current long term investors in Akero Therapeutics, Inc. (NASDAQ: AKRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: AKRO stocks follows a lawsuit filed against Akero Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: AKRO stocks, concerns whether certain Akero Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that approximately 20% of the patients enrolled in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline, that the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH, that the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints, that Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH, and that consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.
Those who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) over potential Wrongdoing here
News-ID: 3863522 • Views: …
More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…

Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…

CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…

Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Akero
Liver Fibrosis Market Set to Grow Substantially Through 2034, DelveInsight Proje …
DelveInsight's "Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The…
Liver Cirrhosis Market Key Trends, Leading Players, and Future Projections Secto …
The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
CoherentMI has released a statistical report titled "Liver Cirrhosis Market Recent Trends, In-depth Analysis, Size, and Forecast 2024-2031." This report offers a comprehensive overview of the competitive landscape, geographical segmentation,…
Deadline on June 25th coming up in Lawsuit for Investors who lost money with sha …
A deadline is coming up on June 25, 2024 in the lawsuit filed for certain investors of Akero Therapeutics, Inc. (NASDAQ: AKRO) over alleged securities laws violations by Akero Therapeutics, Inc. (NASDAQ: AKRO).
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and there are strict and short deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit filed for Investors who lost money with shares of Akero Therapeutics, In …
An investor, who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO), filed a lawsuit over alleged violations of Federal Securities Laws by Akero Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and for certain investors are short and strict deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investors who lost money with Akero Therapeutics, Inc. (NASDAQ: AKRO) should con …
An investigation was announced for investors of Akero Therapeutics, Inc. (NASDAQ: AKRO) shares over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Akero Therapeutics, Inc.…
Sales Mapping Software Market Growth Rate, Share, Overview, Future Scope, and Ke …
The Sales Mapping Software Market report encompasses an exhaustive qualitative and quantitative evaluation. The study includes growth trends, micro- and macro-economic indicators, regulations, and governmental policies. The Sales Mapping Software Market report analyses each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants determine the sub-segments be tapped into to achieve growth in the coming years.
Click Here For a Free…